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Background
Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphos-
phate receptor P2Y12 that has a more rapid onset and more pronounced platelet 
inhibition than clopidogrel.
Methods
In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg 
loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading 
dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 
patients admitted to the hospital with an acute coronary syndrome, with or without 
ST-segment elevation.
Results
At 12 months, the primary end point — a composite of death from vascular causes, 
myocardial infarction, or stroke — had occurred in 9.8% of patients receiving ti-
cagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 
95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing 
of secondary end points showed significant differences in the rates of other com-
posite end points, as well as myocardial infarction alone (5.8% in the ticagrelor 
group vs. 6.9% in the clopidogrel group, P = 0.005) and death from vascular causes 
(4.0% vs. 5.1%, P = 0.001) but not stroke alone (1.5% vs. 1.3%, P = 0.22). The rate of 
death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopid-
ogrel; P<0.001). No significant difference in the rates of major bleeding was found 
between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; 
P = 0.43), but ticagrelor was associated with a higher rate of major bleeding not re-
lated to coronary-artery bypass grafting (4.5% vs. 3.8%, P = 0.03), including more 
instances of fatal intracranial bleeding and fewer of fatal bleeding of other types.
Conclusions
In patients who have an acute coronary syndrome with or without ST-segment eleva-
tion, treatment with ticagrelor as compared with clopidogrel significantly reduced 
the rate of death from vascular causes, myocardial infarction, or stroke without an 
increase in the rate of overall major bleeding but with an increase in the rate of non–
procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
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In patients who have acute coronary syndromes with or without ST-segment eleva-tion, current clinical practice guidelines1-4 
recommend dual antiplatelet treatment with aspi-
rin and clopidogrel. The efficacy of clopidogrel is 
hampered by the slow and variable transforma-
tion of the prodrug to the active metabolite, 
modest and variable platelet inhibition,5,6 an in-
creased risk of bleeding,7,8 and an increased risk 
of stent thrombosis and myocardial infarction in 
patients with a poor response.9 As compared with 
clopidogrel, prasugrel, another thienopyridine 
prodrug, has a more consistent and pronounced 
inhibitory effect on platelets,5,6 resulting in a 
lower risk of myocardial infarction and stent 
thrombosis, but is associated with a higher risk 
of major bleeding in patients with an acute coro-
nary syndrome who are undergoing percutane-
ous coronary intervention (PCI).10
Ticagrelor, a reversible and direct-acting oral 
antagonist of the adenosine diphosphate recep-
tor P2Y12, provides faster, greater, and more con-
sistent P2Y12 inhibition than clopidogrel.11,12 In 
a dose-guiding trial, there was no significant 
difference in the rate of bleeding with the use of 
ticagrelor at a dose of 90 mg or 180 mg twice 
daily and the rate with the use of clopidogrel at 
a dose of 75 mg daily. However, dose-related epi-
sodes of dyspnea and ventricular pauses on Holter 
monitoring, which occurred more frequently with 
ticagrelor, led to the selection of the dose of 90 mg 
twice daily for further studies.13 We conducted 
the Study of Platelet Inhibition and Patient Out-
comes (PLATO) to determine whether ticagrelor 
is superior to clopidogrel for the prevention of 
vascular events and death in a broad population 
of patients presenting with an acute coronary 
syndrome.
Me thods
Study Design
PLATO was a multicenter, randomized, double-
blind trial. The details of the design have been 
published previously.14 The executive and opera-
tions committee, consisting of both academic 
members and representatives of the sponsor, Astra-
Zeneca, designed and oversaw the conduct of the 
trial. An independent data and safety monitoring 
board monitored the trial and had access to the 
unblinded data. The sponsor coordinated the data 
management. Statistical analysis was performed 
by Worldwide Clinical Trials, a contract research 
organization, in collaboration with investigators 
at the academic centers and the sponsor, all of 
whom had full access to the final study data. The 
manuscript was drafted by the chairs of the ex-
ecutive and operations committee, who were aca-
demic authors and who vouch for the accuracy 
and completeness of the reported data. The study 
design was approved by the appropriate national 
and institutional regulatory authorities and ethics 
committees, and all participants provided writ-
ten informed consent.
Study Patients
Patients were eligible for enrollment if they were 
hospitalized for an acute coronary syndrome, with 
or without ST-segment elevation, with an onset 
of symptoms during the previous 24 hours. For 
patients who had an acute coronary syndrome 
without ST-segment elevation, at least two of the 
following three criteria had to be met: ST-seg-
ment changes on electrocardiography, indicating 
ischemia; a positive test of a biomarker, indicat-
ing myocardial necrosis; or one of several risk 
factors (age ≥60 years; previous myocardial infarc-
tion or coronary-artery bypass grafting [CABG]; 
coronary artery disease with stenosis of ≥50% in 
at least two vessels; previous ischemic stroke, 
transient ischemic attack, carotid stenosis of at 
least 50%, or cerebral revascularization; diabetes 
mellitus; peripheral arterial disease; or chronic 
renal dysfunction, defined as a creatinine clear-
ance of <60 ml per minute per 1.73 m2 of body-
surface area). For patients who had an acute 
coronary syndrome with ST-segment elevation, 
the following two inclusion criteria had to be met: 
persistent ST-segment elevation of at least 0.1 mV 
in at least two contiguous leads or a new left 
bundle-branch block, and the intention to per-
form primary PCI. Major exclusion criteria were 
any contraindication against the use of clopido-
grel, fibrinolytic therapy within 24 hours before 
randomization, a need for oral anticoagulation 
therapy, an increased risk of bradycardia, and 
concomitant therapy with a strong cytochrome 
P-450 3A inhibitor or inducer.
Study Treatment
Patients were randomly assigned to receive tica-
grelor or clopidogrel, administered in a double-
blind, double-dummy fashion. Ticagrelor was 
given in a loading dose of 180 mg followed by a 
dose of 90 mg twice daily. Patients in the clopid-
ogrel group who had not received an open-label 
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loading dose and had not been taking clopidogrel 
for at least 5 days before randomization received 
a 300-mg loading dose followed by a dose of 75 
mg daily. Others in the clopidogrel group contin-
ued to receive a maintenance dose of 75 mg daily. 
Patients undergoing PCI after randomization re-
ceived, in a blind fashion, an additional dose of 
their study drug at the time of PCI: 300 mg of clo-
pid ogrel, at the investigator’s discretion, or 90 mg 
of ticagrelor for patients who were undergoing 
PCI more than 24 hours after randomization. In 
patients undergoing CABG, it was recommended 
that the study drug be withheld — in the clopid-
ogrel group, for 5 days, and in the ticagrelor 
group, for 24 to 72 hours. All patients received 
acetylsalicylic acid (aspirin) at a dose of 75 to 
100 mg daily unless they could not tolerate the 
drug. For those who had not previously been re-
ceiving aspirin, 325 mg was the preferred load-
ing dose; 325 mg was also permitted as the daily 
dose for 6 months after stent placement.
Outpatient visits were scheduled at 1, 3, 6, 9, 
and 12 months, with a safety follow-up visit 
1 month after the end of treatment. The ran-
domized treatment was scheduled to continue 
for 12 months, but patients left the study at their 
6- or 9-month visit if the targeted number of 
1780 primary end-point events had occurred by 
that time. Initially, patients were to be assessed 
by means of Holter monitoring for 7 days after 
randomization, until a repeat assessment at 
1 month had been obtained for 2000 of the en-
rolled patients.
End Points
Death from vascular causes was defined as death 
from cardiovascular causes or cerebrovascular 
causes and any death without another known 
cause. Myocardial infarction was defined in ac-
cordance with the universal definition proposed 
in 2007.14,15 Evaluation for stent thrombosis was 
performed according to the Academic Research 
Consortium criteria.16 Stroke was defined as focal 
loss of neurologic function caused by an ischemic 
or hemorrhagic event, with residual symptoms 
lasting at least 24 hours or leading to death.
We defined major life-threatening bleeding as 
fatal bleeding, intracranial bleeding, intrapericar-
dial bleeding with cardiac tamponade, hypo-
volemic shock or severe hypotension due to bleed-
ing and requiring pressors or surgery, a decline in 
the hemoglobin level of 5.0 g per deciliter or 
more, or the need for transfusion of at least 
4 units of red cells. We defined other major 
bleeding as bleeding that led to clinically signifi-
cant disability (e.g., intraocular bleeding with 
permanent vision loss) or bleeding either associ-
ated with a drop in the hemoglobin level of at 
least 3.0 g per deciliter but less than 5.0 g per 
deciliter or requiring transfusion of 2 to 3 units 
of red cells. We defined minor bleeding as any 
bleeding requiring medical intervention but not 
meeting the criteria for major bleeding.
An independent central adjudication commit-
tee adjudicated all suspected primary and sec-
ondary efficacy end points as well as major and 
minor bleeding events.
Statistical Analysis
The primary efficacy variable was the time to the 
first occurrence of composite of death from vas-
cular causes, myocardial infarction, or stroke. 
We estimated that 1780 such events would be re-
quired to achieve 90% power to detect a relative 
risk reduction of 13.5% in the rate of the primary 
end point in the ticagrelor group as compared 
with the clopidogrel group, given an event rate of 
11% in the clopidogrel group at 12 months. Cox 
proportional-hazards models were used to ana-
lyze the data on primary and secondary end 
points. All patients who had been randomly as-
signed to a treatment group were included in the 
intention-to-treat analyses.
The principal secondary efficacy end point was 
the primary efficacy variable studied in the sub-
group of patients for whom invasive management 
was planned at randomization. Additional sec-
ondary end points (analyzed for the entire study 
population) were the composite of death from any 
cause, myocardial infarction, or stroke; the com-
posite of death from vascular causes, myocardial 
infarction, stroke, severe recurrent cardiac isch-
emia, recurrent cardiac ischemia, transient isch-
emic attack, or other arterial thrombotic events; 
myocardial infarction alone; death from cardio-
vascular causes alone; stroke alone; and death 
from any cause.
To address the issue of multiple testing, a 
hierarchical test sequence was planned. The sec-
ondary composite efficacy end points were test-
ed individually, in the order in which they are 
listed above, until the first nonsignificant differ-
ence was found between the two treatment groups. 
Other treatment comparisons were examined in 
an exploratory manner. No multiplicity adjust-
ment was made to the confidence intervals for 
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Table 1. Baseline Characteristics of the Patients, According to Treatment Group.*
Characteristic Ticagrelor Group Clopidogrel Group
Median age — yr 62.0 62.0
Age ≥75 yr — no./total no. (%) 1396/9333 (15.0) 1482/9291 (16.0)
Female sex — no./total no. (%) 2655/9333 (28.4) 2633/9291 (28.3)
Median body weight — kg (range) 80.0 (28–174) 80.0 (29–180)
Body weight <60 kg — no./total no. (%) 652/9333 (7.0) 660/9291 (7.1)
BMI — median (range)† 27 (13–68) 27 (13–70)
Race — no./total no. (%)‡
White 8566/9332 (91.8) 8511/9291 (91.6)
Black 115/9332 (1.2) 114/9291 (1.2)
Asian 542/9332 (5.8) 554/9291 (6.0)
Other 109/9332 (1.2) 112/9291 (1.2)
Cardiovascular risk factor — no./total no. (%)
Habitual smoker 3360/9333 (36.0) 3318/9291 (35.7)
Hypertension 6139/9333 (65.8) 6044/9291 (65.1)
Dyslipidemia 4347/9333 (46.6) 4342/9291 (46.7)
Diabetes mellitus 2326/9333 (24.9) 2336/9291 (25.1)
Other medical history — no./total no. (%)
MI 1900/9333 (20.4) 1924/9291 (20.7)
Percutaneous coronary intervention 1272/9333 (13.6) 1220/9291 (13.1)
Coronary-artery bypass grafting 532/9333 (5.7) 574/9291 (6.2)
Congestive heart failure 513/9333 (5.5) 537/9291 (5.8)
Nonhemorrhagic stroke 353/9333 (3.8) 369/9291 (4.0)
Peripheral arterial disease 566/9333 (6.1) 578/9291 (6.2)
Chronic renal disease 379/9333 (4.1) 406/9291 (4.4)
History of dyspnea 1412/9333 (15.1) 1358/9291 (14.6)
Chronic obstructive pulmonary disease 555/9333 (5.9) 530/9291 (5.7)
Asthma 267/9333 (2.9) 265/9291 (2.9)
Gout 272/9333 (2.9) 262/9291 (2.8)
ECG findings at study entry — no./total no. (%)
Persistent ST-segment elevation 3497/9333 (37.5) 3511/9291 (37.8)
ST-segment depression 4730/9333 (50.7) 4756/9291 (51.2)
T-wave inversion 2970/9333 (31.8) 2975/9291 (32.0)
Positive troponin I test at study entry — no./total no. (%) 7965/9333 (85.3) 7999/9291 (86.1)
Final diagnosis of ACS — no./total no. (%)
ST-elevation MI 3496/9333 (37.5) 3530/9291 (38.0)
Non–ST-elevation MI 4005/9333 (42.9) 3950/9291 (42.5)
Unstable angina 1549/9333 (16.6) 1563/9291 (16.8)
Other diagnosis or missing data§ 283/9333 (3.0) 248/9291 (2.7)
Risk factors for ST-elevation MI — no./total no. (%)
Killip class >2 25/3496 (0.7) 41/3530 (1.2)
TIMI risk score ≥3 1584/3496 (45.3) 1553/3530 (44.0)
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the hazard ratios for the ticagrelor group as 
compared with the clopidogrel group.
The consistency of treatment effects over 
time was assessed by determining the relative 
risk ratios for the periods from randomization 
to 30 days and from 31 to 360 days. Another 
predefined objective was to compare the two 
treatment groups with respect to the occurrence 
of stent thrombosis. The primary safety end point 
was the first occurrence of any major bleeding 
event. Additional safety end points included mi-
nor bleeding, dyspnea, bradyarrhythmia, any other 
clinical adverse event, and results of laboratory 
safety tests. The consistency of effects on effi-
cacy and safety end points was explored in 25 
prespecified subgroups and 8 post hoc sub-
groups, without adjustment for multiple com-
parisons.
R esult s
Study Patients and Study Drugs
We recruited 18,624 patients from 862 centers in 
43 countries from October 2006 through July 
2008. The follow-up period ended in February 
2009, when information on vital status was avail-
able for all patients except five. The two treat-
ment groups were well balanced with regard to 
all baseline characteristics (Table 1) and non-
study medications and procedures (Table 2). 
Both groups started the study drug at a median 
of 11.3 hours (interquartile range, 4.8 to 19.8) 
after the start of chest pain. In the clopidogrel 
group, taking into account both open-label and 
randomized treatment, 79.1% of patients received 
at least 300 mg, and 19.6% at least 600 mg, of 
clopidogrel between the time of the index event 
and up to 24 hours after randomization. Prema-
ture discontinuation of the study drug was slight-
ly more common in the tica grelor group than in 
the clopidogrel group (in 23.4% of patients vs. 
21.5%). The overall rate of adherence to the study 
drug, as assessed by the site investigators, was 
82.8%, and the median duration of exposure to 
the study drug was 277 days (interquartile range, 
179 to 365).
Efficacy
The primary end point occurred significantly less 
often in the ticagrelor group than in the clopid-
ogrel group (in 9.8% of patients vs. 11.7% at 12 
months; hazard ratio, 0.84; 95% confidence in-
terval [CI], 0.77 to 0.92; P<0.001) (Table 3 and 
Fig. 1). The difference in treatment effect was 
apparent within the first 30 days of therapy and 
persisted throughout the study period. As shown 
in Table 3 (and Fig. 1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org), the hierarchical testing of second-
ary end points showed significant reductions in 
the ticagrelor group, as compared with the clopid-
ogrel group, with respect to the rates of the com-
posite end point of death from any cause, myo-
cardial infarction, or stroke (10.2% vs. 12.3%, 
P<0.001); the composite end point of death from 
vascular causes, myocardial infarction, stroke, 
severe recurrent ischemia, recurrent ischemia, 
transient ischemic attack, or other arterial throm-
Table 1. (Continued.)
Characteristic Ticagrelor Group Clopidogrel Group
Risk factors for non–ST-elevation MI — no./total no. (%)¶
Positive troponin I test 4418/5554 (79.5) 4455/5513 (80.8)
ST-segment depression >0.1 mV 3141/5554 (56.6) 3182/5513 (57.7)
TIMI risk score ≥5 1112/5554 (20.0) 1170/5513 (21.2)
* A positive result on testing for troponin I consisted of a troponin I level of 0.08 μg or more per liter for the first sample 
taken, as measured at the central laboratory with the use of the Advia Centaur TnI-Ultra Immunoassay (Siemens). ACS 
denotes acute coronary syndrome, ECG electrocardiographic, MI myocardial infarction, and TIMI Thrombolysis in 
Myocardial Infarction.
† The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
‡ Race was self-reported. “Asian” does not include Indian or Southwest Asian ancestry.
§ This category includes patients with unspecified ACS or no ACS.
¶ Risk factors for non–ST-elevation MI were ascertained for patients with a final ACS diagnosis of non–ST-elevation MI or 
unstable angina.
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Table 2. Randomized Treatment, Other Treatments, and Procedures, According to Treatment Group.*
Characteristic
Ticagrelor Group 
(N = 9333)
Clopidogrel Group 
(N = 9291) P Value†
Start of randomized treatment
Patients receiving treatment — no. (%) 9235 (98.9) 9186 (98.9)
Time after start of chest pain — hr 0.89
Median 11.3 11.3
IQR 4.8–19.8 4.8–19.8
Time after start of hospitalization — hr 0.75
Median 4.9 5.3
IQR 1.3–18.8 1.4–15.8
Premature discontinuation of study drug — no. (%) 2186 (23.4) 1999 (21.5) 0.002
Because of adverse event 690 (7.4) 556 (6.0) <0.001
Because of patient’s unwillingness to continue 946 (10.1) 859 (9.2) 0.04
Other reason 550 (5.9) 584 (6.3) 0.27
Adherence to study drug — no. (%)‡ 7724 (82.8) 7697 (82.8) 0.89
Exposure to study drug — days 0.11
Median 277 277
IQR 177–365 181–365
Clopidogrel administered in hospital before randomization —  
no. (%)
4293 (46.0) 4282 (46.1) 0.91
Clopidogrel dose given (as study drug or not) within 24 hours before 
or after randomization — no. (%)
0.65
No loading dose, or missing information 4937 (52.9) 94 (1.0)
300–375 mg 1921 (20.6) 5528 (59.5)
600–675 mg 1282 (13.7) 1822 (19.6)
Other dose 697 (7.5) 1339 (14.4)
Same dose as that given before index event§ 496 (5.3) 508 (5.5)
Antithrombotic treatment in hospital — no. (%)
Aspirin
Before randomization 8827 (94.6) 8755 (94.2) 0.31
After randomization 9092 (97.4) 9056 (97.5) 0.85
Unfractionated heparin 5304 (56.8) 5233 (56.3) 0.49
Low-molecular-weight heparin 4813 (51.6) 4706 (50.7) 0.21
Fondaparinux 251 (2.7) 246 (2.6) 0.89
Bivalirudin 188 (2.0) 183 (2.0) 0.83
Glycoprotein IIb/IIIa inhibitor 2468 (26.4) 2487 (26.8) 0.62
Other medication administered in hospital or at discharge — no. (%)
Organic nitrate 7181 (76.9) 7088 (76.3) 0.30
Beta-blocker 8339 (89.3) 8336 (89.7) 0.42
ACE inhibitor 7090 (76.0) 6986 (75.2) 0.22
Angiotensin-II–receptor blocker 1143 (12.2) 1125 (12.1) 0.79
Cholesterol-lowering drug (statin) 8373 (89.7) 8289 (89.2) 0.27
Calcium-channel inhibitor 2769 (29.7) 2789 (30.0) 0.61
Proton-pump inhibitor 4233 (45.4) 4128 (44.4) 0.21
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botic events (14.6% vs. 16.7%, P<0.001); myocar-
dial infarction alone (5.8% vs. 6.9%, P = 0.005); 
and death due to vascular causes (4.0% vs. 5.1%, 
P = 0.001). This pattern was also reflected in a 
reduction in the rate of death from any cause 
with ticagrelor (4.5%, vs. 5.9% with clopidogrel; 
P<0.001). The rate of stroke did not differ sig-
nificantly between the two treatment groups, al-
though there were more hemorrhagic strokes 
with ticagrelor than with clopidogrel (23 [0.2%] 
vs. 13 [0.1%], nominal P = 0.10). Concerning our 
first secondary objective of ascertaining the ef-
fect in patients for whom invasive treatment was 
planned, the rate of the primary end point was 
also lower with ticagrelor (8.9%, vs. 10.6% with 
clopidogrel; P = 0.003). Among patients who re-
ceived a stent during the study, the rate of defi-
nite stent thrombosis was lower in the ticagrelor 
group than in the clopidogrel group (1.3% vs. 
1.9%, P = 0.009).
The results regarding the primary end point 
did not show significant heterogeneity in analy-
ses of the 33 subgroups, with three exceptions 
(Fig. 2 in the Supplementary Appendix). The ben-
efit of ticagrelor appeared to be attenuated in 
patients weighing less than the median weight 
for their sex (P = 0.04 for the interaction), those not 
taking lipid-lowering drugs at randomization 
(P = 0.04 for the interaction), and those enrolled 
in North America (P = 0.045 for the interaction).
Bleeding
The ticagrelor and clopidogrel groups did not dif-
fer significantly with regard to the rates of major 
Table 2. (Continued.)
Characteristic
Ticagrelor Group 
(N = 9333)
Clopidogrel Group 
(N = 9291) P Value†
Invasive procedure performed during index hospitalization — no. (%)
Planned invasive treatment 6732 (72.1) 6676 (71.9) 0.68
Coronary angiography 7599 (81.4) 7571 (81.5) 0.91
PCI
During index hospitalization 5687 (60.9) 5676 (61.1) 0.83
Within 24 hours after randomization 4560 (48.9) 4546 (48.9) 0.93
Cardiac surgery 398 (4.3) 434 (4.7) 0.19
Invasive procedure performed during study — no. (%)
PCI 5978 (64.1) 5999 (64.6) 0.46
Stenting 5640 (60.4) 5649 (60.8) 0.61
With bare-metal stent only 3921 (42.0) 3892 (41.9) 0.87
With ≥1 drug-eluting stent 1719 (18.4) 1757 (18.9) 0.40
CABG 931 (10.0) 968 (10.4) 0.32
Time from first dose of study drug to PCI — hr 0.78
Patients with ST-elevation MI
Median 0.25 0.25
IQR 0.05–0.75 0.05–0.72
Patients with non–ST-elevation MI
Median 3.93 3.65
IQR 0.48–46.9 0.45–50.8
* ACE denotes angiotensin-converting enzyme, CABG coronary-artery bypass grafting, IQR interquartile range, and PCI 
percutaneous coronary intervention.
† P values were calculated with the use of Fisher’s exact test.
‡ Adherence to the study drug was defined as use of more than 80% of the study medication during each interval be-
tween visits, as assessed by the site investigator.
§ Patients who had been receiving clopidogrel before the study were not eligible for a loading dose of the drug at study 
entry.
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bleeding as defined in the trial (11.6% and 11.2%, 
respectively; P = 0.43) (Fig. 2 and Table 4). There 
was also no significant difference in the rates of 
major bleeding according to the Thrombolysis in 
Myocardial Infarction (TIMI) criteria (7.9% with 
ticagrelor and 7.7% with clopidogrel, P = 0.57) or 
fatal or life-threatening bleeding (5.8% in both 
groups, P = 0.70). The absence of a significant dif-
ference in major bleeding according to the trial 
definition was consistent among all subgroups, 
without significant heterogeneity, except with re-
gard to the body-mass index (P = 0.05 for interac-
tion) (Fig. 4 in the Supplementary Appendix). The 
two treatment groups did not differ significantly 
in the rates of CABG-related major bleeding or 
bleeding requiring transfusion of red cells. How-
Table 3. Major Efficacy End Points at 12 Months.*
End Point
Ticagrelor  
Group
Clopidogrel  
Group
Hazard Ratio for  
Ticagrelor Group 
(95% CI) P Value†
Primary end point: death from vascular causes, MI, or stroke 
— no./total no. (%)
864/9333 (9.8) 1014/9291 (11.7) 0.84 (0.77–0.92) <0.001‡
Secondary end points — no./total no. (%)
Death from any cause, MI, or stroke 901/9333 (10.2) 1065/9291 (12.3) 0.84 (0.77–0.92) <0.001‡
Death from vascular causes, MI, stroke, severe recurrent 
ischemia, recurrent ischemia, TIA, or other arterial 
thrombotic event
1290/9333 (14.6) 1456/9291 (16.7) 0.88 (0.81–0.95) <0.001‡
MI 504/9333 (5.8) 593/9291 (6.9) 0.84 (0.75–0.95) 0.005‡
Death from vascular causes 353/9333 (4.0) 442/9291 (5.1) 0.79 (0.69–0.91) 0.001‡
Stroke 125/9333 (1.5) 106/9291 (1.3) 1.17 (0.91–1.52) 0.22
Ischemic 96/9333 (1.1) 91/9291 (1.1) 0.74
Hemorrhagic 23/9333 (0.2) 13/9291 (0.1) 0.10
Unknown 10/9333 (0.1) 2/9291 (0.02) 0.04
Other events — no./total no. (%)
Death from any cause 399/9333 (4.5) 506/9291 (5.9) 0.78 (0.69–0.89) <0.001
Death from causes other than vascular causes 46/9333 (0.5) 64/9291 (0.8) 0.71 (0.49–1.04) 0.08
Severe recurrent ischemia 302/9333 (3.5) 345/9291 (4.0) 0.87 (0.74–1.01) 0.08
Recurrent ischemia 500/9333 (5.8) 536/9291 (6.2) 0.93 (0.82–1.05) 0.22
TIA 18/9333 (0.2) 23/9291 (0.3) 0.78 (0.42–1.44) 0.42
Other arterial thrombotic event 19/9333 (0.2) 31/9291 (0.4) 0.61 (0.34–1.08) 0.09
Death from vascular causes, MI, stroke — no./total no. (%)
Invasive treatment planned§ 569/6732 (8.9) 668/6676 (10.6) 0.84 (0.75–0.94) 0.003‡
Event rate, days 1–30 443/9333 (4.8) 502/9291 (5.4) 0.88 (0.77–1.00) 0.045
Event rate, days 31–360¶ 413/8763 (5.3) 510/8688 (6.6) 0.80 (0.70–0.91) <0.001
Stent thrombosis — no. of patients who received a stent/ 
total no. (%)
Definite 71/5640 (1.3) 106/5649 (1.9) 0.67 (0.50–0.91) 0.009
Probable or definite 118/5640 (2.2) 158/5649 (2.9) 0.75 (0.59–0.95) 0.02
Possible, probable, or definite 155/5640 (2.9) 202/5649 (3.8) 0.77 (0.62–0.95) 0.01
* The percentages are Kaplan–Meier estimates of the rate of the end point at 12 months. Patients could have had more than one type of end 
point. Death from vascular causes included fatal bleeding. Only traumatic fatal bleeding was excluded from the category of death from vas-
cular causes. MI denotes myocardial infarction, and TIA transient ischemic attack.
† P values were calculated by means of Cox regression analysis.
‡ Statistical significance was confirmed in the hierarchical testing sequence applied to the secondary composite efficacy end points.
§ A plan for invasive or noninvasive (medical) management was declared before randomization.
¶ Patients with any primary event during the first 30 days were excluded.
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ever, in the ticagrelor group, there was a higher 
rate of non–CABG-related major bleeding ac-
cording to the study criteria (4.5% vs. 3.8%, 
P = 0.03) and the TIMI criteria (2.8% vs. 2.2%, 
P = 0.03) (Fig. 3 in the Supplementary Appendix). 
With ticagrelor as compared with clopidogrel, 
there were more episodes of intracranial bleed-
ing (26 [0.3%] vs. 14 [0.2%], P = 0.06), including 
fatal intracranial bleeding (11 [0.1%] vs. 1 [0.01%], 
P = 0.02). However, there were fewer episodes of 
other types of fatal bleeding in the ticagrelor 
group (9 [0.1%], vs. 21 [0.3%] in the clopidogrel 
group; P = 0.03) (Table 4).
Other Adverse Events
Dyspnea was more common in the ticagrelor 
group than in the clopidogrel group (in 13.8% of 
patients vs. 7.8%) (Table 4). Few patients discon-
tinued the study drug because of dyspnea (0.9% 
of patients in the ticagrelor group and 0.1% in 
the clopidogrel group).
Holter monitoring was performed for a me-
dian of 6 days during the first week in 2866 
patients and was repeated at 30 days in 1991 
patients. There was a higher incidence of ven-
tricular pauses in the first week, but not at day 30, 
in the ticagrelor group than in the clopidogrel 
group (Table 4). Pauses were rarely associated 
with symptoms; the two treatment groups did 
not differ significantly with respect to the inci-
dence of syncope or pacemaker implantation 
(Table 4).
Discontinuation of the study drug due to ad-
verse events occurred more frequently with ti-
cagrelor than with clopidogrel (in 7.4% of pa-
tients vs. 6.0%, P<0.001) (Table 2). The levels of 
creatinine and uric acid increased slightly more 
during the treatment period with ticagrelor than 
with clopidogrel (Table 4).
Discussion
PLATO shows that treatment with ticagrelor as 
compared with clopidogrel in patients with acute 
coronary syndromes significantly reduced the 
rate of death from vascular causes, myocardial 
infarction, or stroke. A similar benefit was seen 
for the individual components of death from vas-
cular causes and myocardial infarction, but not 
for stroke. The beneficial effects of ticagrelor 
were achieved without a significant increase in 
the rate of major bleeding.
The benefits of ticagrelor over clopidogrel 
were seen in patients who had an acute coronary 
syndrome with or without ST-segment elevation. 
Previous trials have shown benefits of clopidogrel 
in the same clinical settings.8,17-19 The advantages 
were seen regardless of whether patients had re-
ceived appropriate initiation of treatment with the 
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Figure 1. Cumulative Kaplan–Meier Estimates of the Time to the First  
Adjudicated Occurrence of the Primary Efficacy End Point.
The primary end point — a composite of death from vascular causes, myo-
cardial infarction, or stroke — occurred significantly less often in the ti-
cagrelor group than in the clopidogrel group (9.8% vs. 11.7% at 12 months; 
hazard ratio, 0.84; 95% confidence interval, 0.77 to 0.92; P<0.001).
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Figure 2. Cumulative Kaplan–Meier Estimates of the Time to the First Major 
Bleeding End Point, According to the Study Criteria.
The time was estimated from the first dose of the study drug in the safety 
population. The hazard ratio for major bleeding, defined according to the 
study criteria, for the ticagrelor group as compared with the clopidogrel 
group was 1.04 (95% confidence interval, 0.95 to 1.13).
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currently recommended higher loading dose of 
clopidogrel and regardless of whether invasive or 
noninvasive management was planned.20-25 The 
treatment effects were the same in the short term 
(days 0 to 30) and in the longer term (days 31 to 
360). This duration of treatment benefit has also 
been shown with clopidogrel.26 Thus, ticagrelor 
appears to expand on the previously demonstrat-
ed benefits of clopidogrel across the spectrum of 
acute coronary syndromes.
Table 4. Safety of the Study Drugs.*
End Point
Ticagrelor  
Group
Clopidogrel  
Group
Hazard or Odds  
Ratio for Ticagrelor 
Group (95% CI)† P Value
Primary safety end points — no./total no. (%)
Major bleeding, study criteria 961/9235 (11.6) 929/9186 (11.2) 1.04 (0.95–1.13) 0.43
Major bleeding, TIMI criteria‡ 657/9235 (7.9) 638/9186 (7.7) 1.03 (0.93–1.15) 0.57
Bleeding requiring red-cell transfusion 818/9235 (8.9) 809/9186 (8.9) 1.00 (0.91–1.11) 0.96
Life-threatening or fatal bleeding, study criteria 491/9235 (5.8) 480/9186 (5.8) 1.03 (0.90–1.16) 0.70
Fatal bleeding 20/9235 (0.3) 23/9186 (0.3) 0.87 (0.48–1.59) 0.66
Nonintracranial fatal bleeding 9/9235 (0.1) 21/9186 (0.3) 0.03
Intracranial bleeding 26/9235 (0.3) 14/9186 (0.2) 1.87 (0.98–3.58) 0.06
Fatal 11/9235 (0.1) 1/9186 (0.01) 0.02
Nonfatal 15/9235 (0.2) 13/9186 (0.2) 0.69
Secondary safety end points — no./total no. (%)
Non–CABG-related major bleeding, study criteria 362/9235 (4.5) 306/9186 (3.8) 1.19 (1.02–1.38) 0.03
Non–CABG-related major bleeding, TIMI criteria 221/9235 (2.8) 177/9186 (2.2) 1.25 (1.03, 1.53) 0.03
CABG-related major bleeding, study criteria 619/9235 (7.4) 654/9186 (7.9) 0.95 (0.85–1.06) 0.32
CABG-related major bleeding, TIMI criteria 446/9235 (5.3) 476/9186 (5.8) 0.94 (0.82–1.07) 0.32
Major or minor bleeding, study criteria 1339/9235 (16.1) 1215/9186 (14.6) 1.11 (1.03–1.20) 0.008
Major or minor bleeding, TIMI criteria‡ 946/9235 (11.4) 906/9186 (10.9) 1.05 (0.96–1.15) 0.33
Dyspnea — no./total no. (%)
Any 1270/9235 (13.8) 721/9186 (7.8) 1.84 (1.68–2.02) <0.001
Requiring discontinuation of study treatment 79/9235 (0.9) 13/9186 (0.1)  6.12 (3.41–11.01) <0.001
Bradycardia — no./total no. (%)
Pacemaker insertion 82/9235 (0.9) 79/9186 (0.9) 0.87
Syncope 100/9235 (1.1) 76/9186 (0.8) 0.08
Bradycardia 409/9235 (4.4) 372/9186 (4.0) 0.21
Heart block 67/9235 (0.7) 66/9186 (0.7) 1.00
Holter monitoring — no./total no. (%)
First week
Ventricular pauses ≥3 sec 84/1451 (5.8) 51/1415 (3.6) 0.01
Ventricular pauses ≥5 sec 29/1451 (2.0) 17/1415 (1.2) 0.10
At 30 days
Ventricular pauses ≥3 sec 21/985 (2.1) 17/1006 (1.7) 0.52
Ventricular pauses ≥5 sec 8/985 (0.8) 6/1006 (0.6) 0.60
Neoplasm arising during treatment — no. of patients/ 
total no. (%)
Any 132/9235 (1.4) 155/9186 (1.7) 0.17
Malignant 115/9235 (1.2) 121/9186 (1.3) 0.69
Benign 18/9235 (0.2) 35/9186 (0.4) 0.02
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The incremental reduction in the risk of coro-
nary thrombotic events (i.e., myocardial infarc-
tion and stent thrombosis) through more-intense 
P2Y12 inhibition with ticagrelor is consistent with 
similar effects of prasugrel.10 As noted above, the 
benefits with ticagrelor were seen regardless of 
whether invasive or noninvasive management was 
planned; this issue has not been investigated with 
other P2Y12 inhibitors. Treatment with ticagrelor 
was also associated with an absolute reduction of 
1.4 percentage points and a relative reduction of 
22% in the rate of death from any cause at 1 year. 
This survival benefit from more-intense platelet 
inhibition with ticagrelor is consistent with reduc-
tions in the mortality rate obtained by means of 
platelet inhibition with aspirin in patients who 
had an acute coronary syndrome27,28 and with 
clopidogrel in patients who had myocardial in-
farction with ST-segment elevation.22 In contrast, 
other contemporary trials involving patients with 
an acute coronary syndrome have not shown sig-
nificant reductions in the mortality rate with the 
use of clopidogrel,8 prasugrel,10 or glycoprotein 
IIb/IIIa inhibitors.29 The improved survival rate 
with ticagrelor might be due to the decrease in 
the risk of thrombotic events without a concomi-
tant increase in the risk of major bleeding, as seen 
with other antithrombotic treatments in patients 
with an acute coronary syndrome.30-32
Since P2Y12 inhibition with ticagrelor is revers-
ible, the antiplatelet effect dissipates more rapidly 
than with the thienopyridines, which are irrevers-
ible P2Y12 inhibitors. Therefore, less procedure-
related bleeding might be expected. Although 
the rates of major bleeding were not lower with 
ticagrelor than with clopidogrel, the more-intense 
platelet inhibition with ticagrelor was not asso-
ciated with an increase in the rate of any major 
bleeding. In contrast to the experience with 
prasugrel,10 which is also a more effective plate-
let inhibitor than clopidogrel but is irreversible, 
there was no increased risk of CABG-related 
bleeding with ticagrelor. As with prasugrel,10 
non–procedure-related bleeding (spontaneous 
bleeding), including gastrointestinal and intrac-
ranial bleeding, was more common with ticagre-
lor than with clopidogrel. Although the rare 
episodes of intracranial bleeding were often fa-
tal, the rates of nonintracranial fatal bleeding, 
death from vascular causes, and death from any 
other cause were lower in the ticagrelor group 
than in the clopidogrel group, resulting in an 
overall reduction in the mortality rate with ti-
cagrelor.
Dyspnea occurred more frequently with ti-
cagrelor than with clopidogrel.13 Most episodes 
lasted less than a week. Discontinuation of the 
study drug because of dyspnea occurred in 0.9% 
of patients in the ticagrelor group. Holter moni-
toring detected more ventricular pauses during 
Table 4. (Continued.)
End Point
Ticagrelor  
Group
Clopidogrel  
Group
Hazard or Odds  
Ratio for Ticagrelor 
Group (95% CI)† P Value
Increase in serum uric acid from baseline value — %
At 1 mo 14±46 7±44 <0.001
At 12 mo 15±52 7±31 <0.001
1 Mo after end of treatment 7±43 8±48 0.56
Increase in serum creatinine from baseline value — %
At 1 mo 10±22 8±21 <0.001
At 12 mo 11±22 9±22 <0.001
1 Mo after end of treatment 10±22 10±22 0.59
* Plus–minus values are means ±SD. Data are shown for patients who received at least one dose of the study drug for events occurring up  
to 7 days after permanent discontinuation of the study drug. The percentages for the primary and secondary safety end points are Kaplan–
Meier estimates of the rate of the end point at 12 months. Patients could have more than one type of end point. CABG denotes coronary- 
artery bypass grafting.
† Hazard ratios are shown for all safety end points except bleeding requiring red-cell transfusion, for which odds ratios are shown. P values 
for the odds ratios were calculated with the use of Fisher’s exact test.
‡ Major bleeding and major or minor bleeding according to Thrombolysis in Myocardial Infarction (TIMI) criteria refer to nonadjudicated 
events analyzed with the use of a statistically programmed analysis in accordance with previously used definitions.10
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the first week in the ticagrelor group than in the 
clopidogrel group,13 but such episodes were in-
frequent at 30 days and were rarely associated 
with symptoms. There were no significant differ-
ences in the rates of clinical manifestations of 
bradyarrhythmia between the two treatment 
groups.
The superiority of ticagrelor over clopidogrel 
with regard to the primary end point, as well as 
the similarity in rates of major bleeding, was 
consistent in 62 of 66 subgroups; the differences 
were significant in the remaining 4 subgroups 
(P<0.05 for heterogeneity). These findings may 
have been due to chance, given the large number 
of tests performed. The difference in results be-
tween patients enrolled in North America and 
those enrolled elsewhere raises the questions of 
whether geographic differences between popula-
tions of patients or practice patterns influenced 
the effects of the randomized treatments, although 
no apparent explanations have been found.
In conclusion, in patients who had an acute 
coronary syndrome with or without ST-segment 
elevation, treatment with ticagrelor, as compared 
with clopidogrel, significantly reduced the rate 
of death from vascular causes, myocardial infarc-
tion, or stroke, without an increase in the rate of 
overall major bleeding but with an increase in 
the rate of non–procedure-related bleeding.
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